Kimberly Schenk published a two part series in the American Institute of CPA’s FVS News. In the first part of the series, she describes the basic framework of a reasonable royalty analysis and in the second part, she provides more detail on approaches that are generally used by experts and accepted by courts for the determination of a reasonable royalty.
Biosimilars: Economic Issues for IP Litigation
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time. This approval has...